The success of clinically relevant immunotherapies requires reversing tumor-induced immunosuppression. Here we demonstrated that linear polyethylenimine-based (PEI-based) nanoparticles encapsulating siRNA were preferentially and avidly engulfed by regulatory DCs expressing CD11c and programmed cell death 1–ligand 1 (PD-L1) at ovarian cancer locations in mice. PEI-siRNA uptake transformed these DCs from immunosuppressive cells to efficient antigen-presenting cells that activated tumor-reactive lymphocytes and exerted direct tumoricidal activity, both in vivo and in situ. PEI triggered robust and selective TLR5 activation in vitro and elicited the production of hallmark TLR5-inducible cytokines in WT mice, but not in Tlr5–/– littermates. Thus, PEI is a TLR5 agonist that, to our knowledge, was not previously recognized. In addition, PEI-complexed nontargeting siRNA oligonucleotides stimulated TLR3 and TLR7. The nonspecific activation of multiple TLRs (specifically, TLR5 and TLR7) reversed the tolerogenic phenotype of human and mouse ovarian tumor–associated DCs. In ovarian carcinoma–bearing mice, this induced T cell–mediated tumor regression and prolonged survival in a manner dependent upon myeloid differentiation primary response gene 88 (MyD88; i.e., independent of TLR3). Furthermore, gene-specific siRNA-PEI nanocomplexes that silenced immunosuppressive molecules on mouse tumor-associated DCs elicited discernibly superior antitumor immunity and enhanced therapeutic effects compared with nontargeting siRNA-PEI nanocomplexes. Our results demonstrate that the intrinsic TLR5 and TLR7 stimulation of siRNA-PEI nanoparticles synergizes with the gene-specific silencing activity of siRNA to transform tumor-infiltrating regulatory DCs into DCs capable of promoting therapeutic antitumor immunity.
Juan R. Cubillos-Ruiz, Xavier Engle, Uciane K. Scarlett, Diana Martinez, Amorette Barber, Raul Elgueta, Li Wang, Yolanda Nesbeth, Yvon Durant, Andrew T. Gewirtz, Charles L. Sentman, Ross Kedl, Jose R. Conejo-Garcia
Title and authors | Publication | Year |
---|---|---|
mRNA Vaccine Nanoplatforms and Innate Immunity.
Wei L, Dong C, Zhu W, Wang BZ |
Viruses | 2024 |
Sulfonium‐Stapled Peptides‐Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention
Zhang Y, Jiang L, Huang S, Lian C, Liang H, Xing Y, Liu J, Tian X, Liu Z, Wang R, An Y, Lu F, Pan Y, Han W, Li Z, Yin F |
Advanced Science | 2024 |
Identification of potential immune-related mechanisms related to the development of multiple myeloma
Wang Y, Zhang W, Li T, Liu M, Gao M, Li X, Chen Y, Song Y, Li W, Du C, Wang F, Liu L |
Chinese Medical Journal | 2024 |
Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells—Function and Therapeutic Potential
Binder AK, Bremm F, Dörrie J, Schaft N |
International journal of molecular sciences | 2024 |
Nanotechnology for boosting ovarian cancer immunotherapy.
Kaur P, Singh SK, Mishra MK, Singh S, Singh R |
Journal of ovarian research | 2024 |
Transgelin 2 guards T cell lipid metabolism and antitumour function.
Hwang SM, Awasthi D, Jeong J, Sandoval TA, Chae CS, Ramos Y, Tan C, Marin Falco M, Salvagno C, Emmanuelli A, McBain IT, Mishra B, Ivashkiv LB, Zamarin D, Cantillo E, Chapman-Davis E, Holcomb K, Morales DK, Yu X, Rodriguez PC, Conejo-Garcia JR, Kaczocha M, Vähärautio A, Song M, Cubillos-Ruiz JR |
Nature | 2024 |
New insights for the development of efficient DNA vaccines
Berger S, Zeyn Y, Wagner E, Bros M |
Microbial Biotechnology | 2024 |
Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter
Zeyn Y, Hobernik D, Wilk U, Pöhmerer J, Hieber C, Medina-Montano C, Röhrig N, Strähle CF, Thoma-Kress AK, Wagner E, Bros M, Berger S |
International journal of molecular sciences | 2023 |
Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function.
Hwang SM, Awasthi D, Jeong J, Sandoval TA, Chae CS, Ramos Y, Tan C, Falco MM, McBain IT, Mishra B, Ivashkiv LB, Zamarin D, Cantillo E, Chapman-Davis E, Holcomb K, Morales DK, Rodriguez PC, Conejo-Garcia JR, Kaczocha M, Vähärautio A, Song M, Cubillos-Ruiz JR |
Research square | 2023 |
A potential cure for tumor-associated immunosuppression by Toxoplasma gondii.
Lotfalizadeh N, Sadr S, Morovati S, Lotfalizadeh M, Hajjafari A, Borji H |
2023 | |
Recent advances in development of nano-carriers for immunogene therapy in various complex disorders
Shahgordi S, Oroojalian F, Hashemi E, Hashemi M |
Iranian Journal of Basic Medical Sciences | 2022 |
Application of lipid-based nanoparticles in cancer immunotherapy
Zhang Z, Yao S, Hu Y, Zhao X, Lee RJ |
Frontiers in immunology | 2022 |
A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.
Meng F, Wang J, He Y, Cresswell GM, Lanman NA, Lyle LT, Ratliff TL, Yeo Y |
Proceedings of the National Academy of Sciences | 2022 |
Bio-Nanomedicine for Cancer Therapy
F Fontana, HA Santos |
2021 | |
Nanotechnology synergized immunoengineering for cancer
DS Chauhan, A Dhasmana, P Laskar, R Prasad, NK Jain, R Srivastava, M Jaggi, SC Chauhan, MM Yallapu |
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V | 2021 |
Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
Á Bella, CA Trani, M Fernández-Sendin, L Arrizabalaga, A Cirella, Á Teijeira, J Medina-Echeverz, I Melero, P Berraondo, F Aranda |
Cancers | 2021 |
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
S Abbasi, S Uchida |
Pharmaceutics | 2021 |
Modulating expression of inhibitory and stimulatory immune ‘checkpoints’ using nanoparticulate-assisted nucleic acid delivery
AA Walters, B Dhadwar, KT Al-Jamal |
EBioMedicine | 2021 |
Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis
H Lemos, E Mohamed, R Ou, C McCardle, X Zheng, K McGuire, NZ Homer, DJ Mole, L Huang, AL Mellor |
Frontiers in immunology | 2020 |
Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics
SV Herck, BG Geest |
Acta Pharmacologica Sinica | 2020 |
Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy
N Thakur, S Thakur, S Chatterjee, J Das, PC Sil |
Frontiers in Chemistry | 2020 |
Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro
R Juneja, H Vadarevu, J Halman, M Tarannum, L Rackley, J Dobbs, J Marquez, M Chandler, K Afonin, JL Vivero-Escoto |
ACS Applied Materials & Interfaces | 2020 |
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
SF Adams, AJ Grimm, CL Chiang, A Mookerjee, D Flies, S Jean, GA McCann, J Michaux, HS Pak, F Huber, C Neal, D Dangaj, M Bassani-Sternberg, S Rusakiewicz, A Facciabene, G Coukos, PA Gimotty, LE Kandalaft |
Journal for ImmunoTherapy of Cancer | 2020 |
Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits
MJ Gorbet, A Singh, C Mao, S Fiering, A Ranjan |
International Journal of Hyperthermia | 2020 |
A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models
C Wang, NF Steinmetz |
Advanced Functional Materials | 2020 |
RNA Nanotechnology-Mediated Cancer Immunotherapy
YX Lin, Y Wang, S Blake, M Yu, L Mei, H Wang, J Shi |
Theranostics | 2020 |
Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors
DM Abarca-Merlin, C Maldonado-Bernal, L Alvarez-Arellano |
BioMed Research International | 2019 |
Engineering Biomaterials to Direct Innate Immunity
RS Oakes, E Froimchuk, CM Jewell |
2019 | |
Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review)
G Zhang, C Liu, H Bai, G Cao, R Cui, Z Zhang |
Oncology Letters | 2019 |
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Y Wu, W Chen, ZP Xu, W Gu |
Frontiers in immunology | 2019 |
Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes
B Corradetti, S Pisano, RS Conlan, M Ferrari |
The Journal of pharmacology and experimental therapeutics | 2019 |
Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses In Vitro
I Flores, D Hevia, A Tittarelli, D Soto, D Rojas-Sepúlveda, C Pereda, F Tempio, C Fuentes, C Falcón-Beas, J Gatica, F Falcón-Beas, M Galindo, F Salazar-Onfray, FE González, MN López |
Journal of Immunology Research | 2019 |
Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor Microenvironment
EB Harrison, SH Azam, CV Pecot |
Frontiers in pharmacology | 2018 |
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
C McCloskey, G Rodriguez, K Galpin, B Vanderhyden |
Cancers | 2018 |
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment
S Sau, HO Alsaab, K Bhise, R Alzhrani, G Nabil, AK Iyer |
Journal of Controlled Release | 2018 |
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
SM Lluesma, M Graciotti, C Chiang, L Kandalaft |
Human vaccines | 2018 |
Polyethylenimine-Dermatan Sulfate Complex, a Bioactive Biomaterial with Unique Toxicity to CD146-Positive Cancer Cells
BK Kim, D Kim, G Kwak, JY Yhee, IC Kwon, SH Kim, Y Yeo |
ACS Biomaterials Science & Engineering | 2017 |
Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine–Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth
G Kwak, D Kim, G Nam, SY Wang, IS Kim, SH Kim, IC Kwon, Y Yeo |
ACS Nano | 2017 |
Polyethylenimine-based micro/nanoparticles as vaccine adjuvants
C Shen, J Li, Y Zhang, Y Li, G Shen, J Zhu, J Tao |
International Journal of Nanomedicine | 2017 |
Polyplex Evolution: Understanding Biology, Optimizing Performance
A Hall, U Lächelt, J Bartek, E Wagner, SM Moghimi |
Molecular Therapy | 2017 |
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells
TL Stephen, KK Payne, RA Chaurio, MJ Allegrezza, H Zhu, J Perez-Sanz, A Perales-Puchalt, JM Nguyen, AE Vara-Ailor, EB Eruslanov, ME Borowsky, R Zhang, TM Laufer, JR Conejo-Garcia |
Immunity | 2017 |
Evaluation of a nanotechnology-based approach to induce gene-expression in human THP-1 macrophages under inflammatory conditions
L Bernal, A Alvarado-Vázquez, DW Ferreira, CA Paige, C Ulecia-Morón, B Hill, M Caesar, EA Romero-Sandoval |
Immunobiology | 2017 |
Making allies of phagocytes
S Fiering |
Nature Nanotechnology | 2017 |
Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
Chae CS, Teran-Cabanillas E, Cubillos-Ruiz JR |
Cancer Immunology, Immunotherapy | 2017 |
Emerging nanotechnologies for cancer immunotherapy
S Shukla, NF Steinmetz |
Experimental biology and medicine (Maywood, N.J.) | 2016 |
Delivery strategies and potential targets for siRNA in major cancer types
SJ Lee, MJ Kim, IC Kwon, TM Roberts |
Advanced Drug Delivery Reviews | 2016 |
Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity
X Yu, H Wang, X Li, C Guo, F Yuan, PB Fisher, XY Wang |
Cancer research | 2016 |
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
H Zhu, F Bengsch, N Svoronos, MR Rutkowski, BG Bitler, MJ Allegrezza, Y Yokoyama, AV Kossenkov, JE Bradner, JR Conejo-Garcia, R Zhang |
Cell Reports | 2016 |
FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET
A Perales-Puchalt, N Svoronos, MR Rutkowski, MJ Allegrezza, AJ Tesone, KK Payne, J Wickramasinghe, JM Nguyen, SW O'Brien, K Gumireddy, Q Huang, M Cadungog, DC Connolly, J Tchou, TJ Curiel, JR Conejo-Garcia |
Clinical cancer research | 2016 |
IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors
MJ Allegrezza, MR Rutkowski, TL Stephen, N Svoronos, AJ Tesone, A Perales-Puchalt, JM Nguyen, F Sarmin, MR Sheen, EK Jeng, J Tchou, HC Wong, SN Fiering, JR Conejo-Garcia |
Cancer research | 2016 |
Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells
AJ Tesone, MR Rutkowski, E Brencicova, N Svoronos, A Perales-Puchalt, TL Stephen, MJ Allegrezza, KK Payne, JM Nguyen, J Wickramasinghe, J Tchou, ME Borowsky, GA Rabinovich, AV Kossenkov, JR Conejo-Garcia |
Cell Reports | 2016 |
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103 + dendritic cells in late-stage ovarian cancer
DB Flies, T Higuchi, JC Harris, V Jha, PA Gimotty, SF Adams |
OncoImmunology | 2016 |
Multifunctional nanoparticles for cancer immunotherapy
T Saleh, SA Shojaosadati |
Human Vaccines & Immunotherapeutics | 2016 |
Targeting of cancer‑associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment
M Li, M Li, T Yin, H Shi, Y Wen, B Zhang, M Chen, G Xu, K Ren, Y Wei |
Molecular medicine reports | 2016 |
Cancer-Associated Myeloid Regulatory Cells
YD Vlaeminck, A González-Rascón, C Goyvaerts, K Breckpot |
Frontiers in immunology | 2016 |
State-of-the-art of regulatory dendritic cells in cancer
JR Conejo-Garcia, MR Rutkowski, JR Cubillos-Ruiz |
Pharmacology & Therapeutics | 2016 |
Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy
W He, P Liang, G Guo, Z Huang, Y Niu, L Dong, C Wang, J Zhang |
Scientific Reports | 2016 |
Efficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)
MA Foxley, AW Friedline, JM Jensen, SL Nimmo, EM Scull, JB King, S Strange, MT Xiao, BE Smith, KJ Thomas, DT Glatzhofer, RH Cichewicz, CV Rice |
The Journal of Antibiotics | 2016 |
Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells
N Svoronos, A Perales-Puchalt, MJ Allegrezza, MR Rutkowski, KK Payne, AJ Tesone, JM Nguyen, TJ Curiel, MG Cadungog, S Singhal, EB Eruslanov, P Zhang, J Tchou, R Zhang, JR Conejo-Garcia |
Cancer Discovery | 2016 |
Endogenous and tumour-derived microRNAs regulate cross-presentation in dendritic cells and consequently cytotoxic T cell function
S Kikete, X Chu, L Wang, Y Bian |
Cytotechnology | 2016 |
Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation
MR Rutkowski, TL Stephen, N Svoronos, MJ Allegrezza, AJ Tesone, A Perales-Puchalt, E Brencicova, X Escovar-Fadul, JM Nguyen, MG Cadungog, R Zhang, M Salatino, J Tchou, GA Rabinovich, JR Conejo-Garcia |
Cancer Cell | 2015 |
Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells
S Maiolino, A Russo, V Pagliara, C Conte, F Ungaro, G Russo, F Quaglia |
Journal of nanobiotechnology | 2015 |
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
Z Guo, H Wang, F Meng, J Li, S Zhang |
Journal of Translational Medicine | 2015 |
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
JR Cubillos-Ruiz, PC Silberman, MR Rutkowski, S Chopra, A Perales-Puchalt, M Song, S Zhang, SE Bettigole, D Gupta, K Holcomb, LH Ellenson, T Caputo, AH Lee, JR Conejo-Garcia, LH Glimcher |
Cell | 2015 |
Dendritic cells are stressed out in tumor
T Maj, W Zou |
Cell Research | 2015 |
Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy
JR Cubillos-Ruiz, LH Glimcher |
OncoImmunology | 2015 |
Safety of nanoparticles in medicine
Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H, Ferrari M, Zhao Y |
Current drug targets | 2015 |
A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis
P Caballero-Campo, MG Buffone, F Benencia, JR Conejo-García, PF Rinaudo, GL Gerton |
Journal of Cellular Physiology | 2014 |
Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease
F Sipos |
World journal of gastroenterology : WJG | 2014 |
Perspectives on Reprograming Cancer-Associated Dendritic Cells for Anti-Tumor Therapies
F Benencia, M Muccioli, M Alnaeeli |
Frontiers in Oncology | 2014 |
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
L Lu, X Xu, B Zhang, R Zhang, H Ji, X Wang |
Journal of Translational Medicine | 2014 |
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer
Z Guo, X Wang, D Cheng, Z Xia, M Luan, S Zhang |
PloS one | 2014 |
The Role of MicroRNAs in Ovarian Cancer
Y Kinose, K Sawada, K Nakamura, T Kimura |
BioMed Research International | 2014 |
Transforming Growth Factor β-Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression
TL Stephen, MR Rutkowski, MJ Allegrezza, A Perales-Puchalt, AJ Tesone, N Svoronos, JM Nguyen, F Sarmin, ME Borowsky, J Tchou, JR Conejo-Garcia |
Immunity | 2014 |
Reprogramming immune responses via microRNA modulation
JR Cubillos-Ruiz, MR Rutkowski, J Tchou, JR Conejo-Garcia |
2014 | |
Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery
BR Smith, EE Ghosn, H Rallapalli, JA Prescher, T Larson, LA Herzenberg, SS Gambhir |
Nature Nanotechnology | 2014 |
Stimulating antitumor immunity with nanoparticles
MR Sheen, PH Lizotte, S Toraya-Brown, S Fiering |
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology | 2014 |
Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics
Engelberth SA, Hempel N, Bergkvist M |
Critical Reviews in Oncogenesis | 2014 |
Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity
JS Dolina, SS Sung, TI Novobrantseva, TM Nguyen, YS Hahn |
Molecular Therapy — Nucleic Acids | 2013 |
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin
H Wei, L Zhao, W Li, K Fan, W Qian, S Hou, H Wang, M Dai, I Hellstrom, KE Hellstrom, Y Guo |
PloS one | 2013 |
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Z Guo, D Cheng, Z Xia, M Luan, L Wu, G Wang, S Zhang |
Journal of Translational Medicine | 2013 |
Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer
AJ Tesone, N Svoronos, MJ Allegrezza, JR Conejo-Garcia |
Frontiers in immunology | 2013 |
The Yin and Yang of Toll-like receptors in cancer
JP Pradere, DH Dapito, RF Schwabe |
Oncogene | 2013 |
New aspects of gene-silencing for the treatment of cardiovascular diseases
O Koenig, T Walker, N Perle, A Zech, B Neumann, C Schlensak, HP Wendel, A Nolte |
Pharmaceuticals (Basel, Switzerland) | 2013 |
Delivery of gene silencing agents for breast cancer therapy
H Shen, V Mittal, M Ferrari, J Chang |
Breast Cancer Research | 2013 |
Cytokines as biomarkers of nanoparticle immunotoxicity
M Elsabahy, KL Wooley |
Chemical Society Reviews | 2013 |
IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis
AE Reeme, HE Miller, RT Robinson |
Tuberculosis | 2013 |
Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles
M Elsabahy, S Zhang, F Zhang, ZJ Deng, YH Lim, H Wang, P Parsamian, PT Hammond, KL Wooley |
Scientific Reports | 2013 |
Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy
AY Lin, JP Almeida, A Bear, N Liu, L Luo, AE Foster, RA Drezek |
PloS one | 2013 |
Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy
S Toraya-Brown, MR Sheen, JR Baird, S Barry, E Demidenko, MJ Turk, PJ Hoopes, JR Conejo-Garcia, S Fiering |
Integrative biology : quantitative biosciences from nano to macro | 2013 |
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment
JR Baird, BA Fox, KL Sanders, PH Lizotte, JR Cubillos-Ruiz, UK Scarlett, MR Rutkowski, JR Conejo-Garcia, S Fiering, DJ Bzik |
Cancer research | 2013 |
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines
BA Fox, KL Sanders, S Chen, DJ Bzik |
Trends in Parasitology | 2013 |
Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes
JL Cervantes, CJ la Vake, B Weinerman, S Luu, C O'Connell, PH Verardi, JC Salazar |
Journal of leukocyte biology | 2013 |
Toxicity profiling of several common RNAi-based nanomedicines: a comparative study
D Landesman-Milo, D Peer |
Drug Delivery and Translational Research | 2013 |
REPROGRAMMING TUMOR-ASSOCIATED DENDRITIC CELLS IN VIVO USING MICRORNA MIMETICS TRIGGERS PROTECTIVE IMMUNITY AGAINST OVARIAN CANCER
JR Cubillos-Ruiz, JR Baird, AJ Tesone, MR Rutkowski, UK Scarlett, AL Camposeco-Jacobs, J Anadon-Arnillas, NM Harwood, M Korc, SN Fiering, LF Sempere, JR Conejo-Garcia |
Cancer research | 2012 |
Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor Vaccination
F Benencia, L Sprague, J McGinty, M Pate, M Muccioli |
Journal of Biomedicine and Biotechnology | 2012 |
Toll-Like Receptors as Novel Therapeutic Targets for Ovarian Cancer
M Muccioli, L Sprague, H Nandigam, M Pate, F Benencia |
ISRN Oncology | 2012 |
Nanovector delivery of siRNA for cancer therapy
H Shen, T Sun, M Ferrari |
Cancer Gene Therapy | 2012 |
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
RL Kanasty, KA Whitehead, AJ Vegas, DG Anderson |
Molecular Therapy | 2012 |
Small Interfering RNA Targeted to IGF-IR Delays Tumor Growth and Induces Proinflammatory Cytokines in a Mouse Breast Cancer Model
T Durfort, M Tkach, MI Meschaninova, MA Rivas, PV Elizalde, AG Venyaminova, R Schillaci, JC François |
PloS one | 2012 |
Anti-tumor immunity: Myeloid leukocytes control the immune landscape
MR Rutkowski, TL Stephen, JR Conejo-Garcia |
Cellular Immunology | 2012 |
Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy
UK Scarlett, JR Conejo-Garcia |
Expert Review of Obstetrics & Gynecology | 2012 |
Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles
JR Cubillos-Ruiz, LF Sempere, JR Conejo-Garcia |
OncoImmunology | 2012 |
Anti-radiation damage effect of polyethylenimine as a toll-like receptor 5 targeted agonist
Z Hu, Y Xing, Y Qian, X Chen, J Tu, L Ren, K Wang, Z Chen |
Journal of Radiation Research | 2012 |
Adhesion to substrates induces dendritic cell endothelization and decreases immunological response
J Osterbur, L Sprague, M Muccioli, M Pate, K Mansfield, J McGinty, Y Li, Y Li, V Shirure, MC Courreges, F Benencia |
Immunobiology | 2012 |
Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants
SK Eszterhas, NO Ilonzo, JE Crozier, S Celaj, AL Howell |
Infectious disease reports | 2011 |
Age-Related Macular Degeneration and the Other Double Helix The Cogan Lecture
J Ambati |
Investigative ophthalmology & visual science | 2011 |
Current prospects for RNA interference-based therapies
BL Davidson, PB McCray |
Nature Reviews Genetics | 2011 |
The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells
L Sprague, M Muccioli, M Pate, E Meles, J McGinty, H Nandigam, AK Venkatesh, MY Gu, K Mansfield, A Rutowski, O Omosebi, MC Courreges, F Benencia |
BMC Immunology | 2011 |
Nanoparticle preconditioning for enhanced thermal therapies in cancer
MM Shenoi, NB Shah, RJ Griffin, GM Vercellotti, JC Bischof |
Nanomedicine (London, England) | 2011 |
Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors
CY Wu, HY Yang, A Monie, B Ma, HH Tsai, TC Wu, CF Hung |
Cancer Immunology, Immunotherapy | 2011 |
Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles
T Tanaka, LS Mangala, PE Vivas-Mejia, R Nieves-Alicea, AP Mann, E Mora, HD Han, MM Shahzad, X Liu, R Bhavane, J Gu, JR Fakhoury, C Chiappini, C Lu, K Matsuo, B Godin, RL Stone, AM Nick, G Lopez-Berestein, AK Sood, M Ferrari |
Cancer research | 2010 |
Harnessing the Effect of Adoptively Transferred Tumor-Reactive T Cells on Endogenous (Host-Derived) Antitumor Immunity
Y Nesbeth, JR Conejo-Garcia |
Clinical and Developmental Immunology | 2010 |
Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy
YZ Chen, XL Yao, Y Tabata, S Nakagawa, JQ Gao |
Clinical and Developmental Immunology | 2010 |
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells
YC Nesbeth, DG Martinez, S Toraya, UK Scarlett, JR Cubillos-Ruiz, MR Rutkowski, JR Conejo-Garcia |
Journal of immunology (Baltimore, Md. : 1950) | 2010 |
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR |
Cell cycle (Georgetown, Tex.) | 2010 |
CD277 is a Negative Co-stimulatory Molecule Universally Expressed by Ovarian Cancer Microenvironmental Cells
Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR |
Oncotarget | 2010 |
Autophagy links pattern recognition receptors to tumor cell apoptosis
J Vollmer |
Molecular Therapy | 2009 |
Nanomolecular targeting of dendritic cells for ovarian cancer therapy
JR Cubillos-Ruiz, S Fiering, JR Conejo-Garcia |
Future oncology (London, England) | 2009 |
Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma
GW Stone, S Barzee, V Snarsky, C Santucci, B Tran, R Langer, GT Zugates, DG Anderson, RS Kornbluth |
PloS one | 2009 |
IN SITU STIMULATION OF CD40 AND TOLL-LIKE RECEPTOR 3 TRANSFORMS OVARIAN CANCER-INFILTRATING DENDRITIC CELLS FROM IMMUNOSUPPRESSIVE TO IMMUNOSTIMULATORY CELLS
Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL, Conejo-Garcia JR |
Cancer research | 2009 |